Claims for Patent: 8,754,091

Summary for Patent: 8,754,091

Title:	Inhibitors of bruton's tyrosine kinase
Abstract:	Disclosed herein are compounds, including compounds having the structure of Formula (A), (B), (C), and (D), as described in further detail herein, that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
Inventor(s):	Honigberg; Lee (San Francisco, CA), Verner; Erik (Belmont, CA), Pan; Zhengying (Austin, TX)
Assignee:	Pharmacyclics, Inc. (Sunnyvale, CA)
Application Number:	13/542,440
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,754,091
Patent Claims:	1. A pharmaceutical formulation comprising an irreversible, Bruton's tyrosine kinase (Btk) inhibitor having the structure of Formula (A): ##STR00056## wherein: A is N; R.sub.1 is L.sub.2-(substituted or unsubstituted heteroaryl) or L.sub.2-(substituted or unsubstituted aryl), where L.sub.2 is a bond, O, S, --S(.dbd.O), --S(.dbd.O).sub.2, C(.dbd.O), -(substituted or unsubstituted C.sub.1-C.sub.6alkylene), or -(substituted or unsubstituted C.sub.2-C.sub.6-alkenylene); R.sub.2 and R.sub.3 are independently H or lower alkyl; R.sub.4 is L.sub.3-X-L.sub.4-G, wherein, L.sub.3 is optional, and when present is an optionally substituted or unsubstituted alkylene, optionally substituted or unsubstituted cycloalkylene, optionally substituted or unsubstituted alkenylene, or optionally substituted or unsubstituted alkynylene; X is optional, and when present is O, --C(.dbd.O), S, --S(.dbd.O), --S(.dbd.O).sub.2, --NH, --NR.sub.9, --NHC(O), --C(O)NH, --NR.sub.9C(O), --C(O)NR.sub.9, --S(.dbd.O).sub.2NH, --NHS(.dbd.O).sub.2, --S(.dbd.O).sub.2NR.sub.9--, --NR.sub.9S(.dbd.O).sub.2, --OC(O)NH--, --NHC(O)O--, --OC(O)NR.sub.9--, --NR.sub.9C(O)O--, --CH.dbd.NO--, --ON.dbd.CH--, --NR.sub.10C(O)NR.sub.10--, heteroarylene, arylene, --NR.sub.10C(.dbd.NR.sub.11)NR.sub.10--, --NR.sub.10C(.dbd.NR.sub.11)--, --C(.dbd.NR.sub.11)NR.sub.10--, --OC(.dbd.NR.sub.11)--, or --C(.dbd.NR.sub.11)O--; L.sub.4 is optional, and when present is a substituted or unsubstituted alkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted alkenylene, substituted or unsubstituted alkynylene, substituted or unsubstituted arylene, substituted or unsubstituted heteroarylene, or substituted or unsubstituted heterocyclene; or L.sub.3, X and L.sub.4 taken together form a nitrogen containing heterocyclic ring; G is ##STR00057## wherein, R.sub.6, R.sub.7 and R.sub.8 are independently selected from among H, lower alkyl or substituted lower alkyl, lower heteroalkyl or substituted lower heteroalkyl, substituted or unsubstituted lower cycloalkyl, and substituted or unsubstituted lower heterocycloalkyl; R.sub.9 is selected from among H, substituted or unsubstituted lower alkyl, and substituted or unsubstituted lower cycloalkyl; each R.sub.10 is independently H, substituted or unsubstituted lower alkyl, or substituted or unsubstituted lower cycloalkyl; or two R.sub.10 groups can together form a 5-, 6-, 7-, or 8-membered heterocyclic ring; or R.sub.10 and R.sub.11 can together form a 5-, 6-, 7-, or 8-membered heterocyclic ring; and R.sub.11 is selected from H, --S(.dbd.O).sub.2R.sub.8, --S(.dbd.O).sub.2NH.sub.2, --C(O)R.sub.8, --CN, --NO.sub.2, heteroaryl, or heteroalkyl; or a pharmaceutically acceptable solvate, hydrate, or salt thereof, and a pharmaceutically acceptable excipient. 2. The pharmaceutical formulation of claim 1, wherein the irreversible, Btk inhibitor is a compound of Formula (D) having the structure: ##STR00058## wherein: L.sub.a is O or S; Ar is phenyl; Y is a 4-, 5-, 6-, or 7-membered cycloalkylene ring, or Y is azetidinyl, pyrrolidinyl, piperidinyl, or azepanyl; Z is C(.dbd.O), OC(.dbd.O), NHC(.dbd.O), S(.dbd.O).sub.x, or NHS(.dbd.O).sub.x, where x is 2; R.sub.8 and R.sub.7 are H; or R.sub.7 and R.sub.8 taken together form a bond; and R.sub.6 is H; or a pharmaceutically acceptable solvate, hydrate, or salt thereof. 3. The pharmaceutical formulation of claim 1 formulated for a route of administration selected from oral administration, parenteral administration, buccal administration, nasal administration, topical administration, or rectal administration. 4. The pharmaceutical formulation of claim 3 formulated for oral administration. 5. The pharmaceutical formulation of claim 4, wherein the pharmaceutical formulation is in solid dosage form. 6. The pharmaceutical formulation of claim 5, wherein the pharmaceutical formulation is contained in one or more capsules. 7. The pharmaceutical formulation of claim 5, wherein the pharmaceutically acceptable excipient comprises one or more carrier materials selective from the group consisting of binders, disintegration agents, surfactants, lubricants, and combinations thereof. 8. The pharmaceutical formulation of claim 7, wherein the pharmaceutically acceptable excipient comprises a binder, a disintegration agent, and a surfactant. 9. The pharmaceutical formulation of claim 8, wherein the binder is present in the pharmaceutical formulation at an amount of from 20 to 70 w/w %. 10. The pharmaceutical formulation of claim 9, wherein the binder is microcrystalline cellulose. 11. The pharmaceutical formulation of claim 8, wherein the disintegration agent is croscarmellose sodium. 12. The pharmaceutical formulation of claim 8, wherein the surfactant is sodium lauryl sulfate. 13. The pharmaceutical formulation of claim 8, wherein the pharmaceutically acceptable excipient further comprises a lubricant. 14. The pharmaceutical formulation of claim 13, wherein the lubricant is magnesium stearate. 15. The pharmaceutical formulation of claim 1, wherein the compound of Formula (A) has the structure: ##STR00059## Y and R.sub.12 taken together form a 4-, 5-, or 6-membered heterocyclic ring; and G is ##STR00060## wherein, R.sub.6, R.sub.7 and R.sub.8 are independently selected from among H, lower alkyl or substituted lower alkyl, lower heteroalkyl or substituted lower heteroalkyl, substituted or unsubstituted lower cycloalkyl, and substituted or unsubstituted lower heterocycloalkyl; or a pharmaceutically acceptable solvate, hydrate, or salt thereof. 16. The pharmaceutical formulation of claim 15, wherein Y and R.sub.12 taken together form a 6-membered heterocyclic ring. 17. The pharmaceutical formulation of claim 15, wherein G is ##STR00061## 18. The pharmaceutical formulation of claim 15, wherein R.sub.6, R.sub.7, and R.sub.8 are independently H. 19. The pharmaceutical formulation of claim 2, wherein La is O, Z is C(O), and R.sub.6, R.sub.7, and R.sub.8 are independently H. 20. The pharmaceutical formulation of claim 1, wherein the irreversible Btk inhibitor is a compound having the structure: ##STR00062## or a pharmaceutically acceptable solvate, hydrate, or salt thereof. 21. A pharmaceutical formulation comprising an irreversible Btk inhibitor having the structure: ##STR00063## and a pharmaceutically acceptable excipient.